Status
Conditions
Treatments
About
Prospective, multicenter non comparative and observational study (post-market clinical follow-up).
Patients operated with PASS OCT® manufactured by MEDICREA® INTERNATIONAL between July 2016 and July 2017.
The inclusion period will be 12 months and the follow-up 24 months
Full description
The primary endpoint is to evaluate the safety of the PASS OCT® system.
The secondary endpoints are to analyze the efficacy of the system with several point of view:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patient with
Patient operated with PASS OCT®
Patient > 18 years
Patient affiliated to health care insurance (social security in France)
Patient able to complete a self-administered questionnaire
Patient able to understand the protocol and the planning visit
Patient able to sign an informed consent form
Exclusion criteria
Loading...
Central trial contact
Estelle Douceron, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal